VivoSim Labs, INC. VIVS
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-08-02
VivoSim Labs, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -8768.7% | -8761.1% | -13840.4% | -4792.2% | -765.3% | — | -977.9% | -882.4% | -766.3% | -911.9% |
| Net margin | -10567.2% | -1727.8% | -13459.6% | -4664.6% | -763.2% | — | -852.0% | -861.7% | -756.1% | -908.9% |
| FCF margin | -8264.9% | -6579.2% | -13481.7% | -3460.5% | -590.8% | — | -677.7% | -661.7% | -631.8% | -722.0% |
| Return on assets | -187.4% | -17.0% | -231.1% | -85.0% | -34.4% | -42.2% | -65.8% | -65.6% | -69.8% | -55.6% |
| Return on equity | 1259.6% | -23.7% | -407.4% | -112.6% | -37.9% | -42.9% | -70.3% | -73.4% | -78.1% | -61.7% |
| Current ratio | 2.38 | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 | 10.32 | 10.04 | 10.83 |
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.